Neuropilin 1 (NRP1) is a transmembrane glycoprotein that acts as a co-receptor for multiple extracellular ligands and typically performs growth-promoting functions in cancer cells. Accumulating evidence indicates that NRP1 is upregulated, and may be an independent predictor of cancer relapse and poor survival, in many cancer types, including non-small cell lung cancer (NSCLC). Recent evidence suggests that NRP1 affects tumour cell viability via the epidermal growth factor receptor (EGFR) and Erb-B2 receptor tyrosine kinase 2 (ErbB2) signalling pathways in venous endothelial cells and in multiple cancer cells. In the present study, we aimed to evaluate the role of NRP1 in NSCLC tumourigenesis and to explore a new post-transcriptional mechanism of NRP1 regulation via a microRNA that mediates EGFR signalling regulation in lung carcinogenesis. The results showed that miR-338-3p is poorly expressed and NRP1 is overexpressed in NSCLC tissues relative to their levels in adjacent noncancerous tissues. Luciferase reporter assays, quantitative real-time reverse transcription PCR, and Western blot analyses showed that NRP1 is a direct target of miR-338-3p. Overexpression of miR-338-3p in NSCLC cell lines inhibited cell proliferation in vitro and in vivo. Moreover, cell migration and invasion were inhibited by miR-338-3p overexpression. These effects occurred via the EGF signalling pathway. Our data revealed a new post-transcriptional mechanism by which miR-338-3p directly targets NRP1; this mechanism plays a role in enhancing drug sensitivity in EGFR wild-type patients with NSCLC.
| INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide, and approximately 85% of all lung cancers are non-small cell lung cancer (NSCLC). 1, 2 Despite improvements in therapeutic strategies, the survival, and outcome of patients with NSCLC have not changed dramatically. 3 At diagnosis, most patients have advanced stage disease that is past the optimal treatment period. Therefore, understanding the pathogenesis of NSCLC and identifying new treatment targets are important.
Neuropilins (NRPs) are multifunctional proteins involved in development, immunity, and cancer. Neuropilin 1 (NRP1) and its homologue neuropilin 2 (NRP2) are coreceptors that interact with multiple growth factors. 4 A study by Kawakami et al demonstrated that the expression level of the NRP1 gene in neoplastic tissue was higher than that in extra neoplastic lung tissue; 55 of 68 NSCLC specimens were positive for NRP1 gene expression (80.9%). 5 Another study reported that patients with high NRP1 expression had shorter diseasefree and overall survival times compared with patients with low NRP1 expression. 6 In addition, recent evidence suggests that NRP1 affects tumor cell viability via the epidermal growth factor receptor (EGFR)
and Erb-B2 receptor tyrosine kinase 2 (ErbB2) signalling pathways in venous endothelial cells and in multiple cancer cells. 7, 8 A molecular biomarker that predicts the efficacy of an EGFR-tyrosine kinase inhibitor(s) (TKI(s)) in patients with lung cancer with wild-type EGFR has yet to be established. However, some patients with lung cancer with wild-type EGFR benefit from EGFR-TKI therapy, 9, 10 possibly because resistance to EGFR-TKIs can be mediated through multiple signalling pathways that converge upon cap-dependent translation in NSCLC cells expressing wild-type EGFR. 11, 12 Interestingly, our previous study showed that CD73 affected the efficacy of EGFR-targeted therapies in NSCLC cells with wild-type EGFR. 13 Thus, based on the literature, we hypothesized that NRP1 plays a role in the EGF signalling pathway and that knockdown of NRP1 expression might sensitize NSCLC cells to therapeutic agents. To determine whether knockdown of NRP1 expression could sensitize NSCLC cells to EGFR-TKI, we assessed the viability of NRP1-silenced and control cells exposed to gefitinib.
Our data showed that NRP1 inhibition significantly improved the effects of EGFR-TKIs in vitro.
As the most abundant family of small single-stranded noncoding RNA gene products, microRNAs (miRNAs) play roles in the maintenance of cellular homeostasis. 14 MiRNAs are critical in attenuating the stability and translation of mRNAs via base pairing to partially complementary sites in the 3′ untranslated region (3′-UTR) of their target genes and are involved in multiple physiological and pathological processes. 14, 15 Recently, dysregulation of miRNAs has been shown to be associated with tumour growth, metastasis, diagnosis, and prognosis. [16] [17] [18] [19] For example, a comprehensive expression analysis of numerous miRNAs reflected the developmental lineage and differentiation state of human cancers, including lung cancer. 20 Studies have
shown that the prognosis of cancer is closely related to the altered expression of miRNAs in cancer tissues and in specific expression signatures or panels, 21 which can also be used to classify human cancers and distinguish tumour subtypes. 22 In particular, accumulating evidence indicates that miRNAs are closely related to the development of human lung cancer. 23, 24 We previously used miRNA arrays to identify miRNAs that might affect various cellular pathways and biological processes. Among the identified miRNAs, microRNA-338-3p was significantly downregulated in NSCLC tissues. 25 In the present study, to identify further novel targets of miR-338-3p that might play an important role in NSCLC, we predicted its target mRNAs using computational algorithms. Interestingly, miR-338-3p was predicted to bind to the 3′-UTR of NRP1 mRNA (encoding neuropilin 1), indicating that miR-338-3p might be involved in regulating NRP1 and the NRP1-mediated EGF signalling pathway during lung cancer progression.
In the present study, we evaluated the role of NRP1 in NSCLC tumourigenesis and explored the possible role of miR-338-3p in the regulation of NRP1 expression. We found that the regulation of NRP1
by miR-338-3p affects EGFR-TKI-mediated drug sensitivity in lung carcinogenesis.
| MATERIAL AND METHODS

| Patients and samples
All participants provided written informed consent for the whole 
| Gene expression and survival analysis
The oncomine database (https://www.oncomine.org) was selected to compare NRP1 expression between the NSCLC group and the normal control group (adjusted P < 0.05 and an absolute log2 fold change >2).
We also used the Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/index.html), which performs overall survival (OS) or disease free survival (DFS, also called relapse-free survival and RFS) analysis based on gene expression.
GEPIA uses the log-rank test (also known as the Mantel-Cox test) for hypothesis testing. Cohort thresholds can be adjusted, and gene-pairs can be used. GEPIA will generate a survival plot based on user custom input parameters. Using Kaplan-Meier Plotter (http://kmplot.com/), we generated two survival curves to show the association between the expression of NRP1 and the OS of patients with the auto-select best cut-off value. The GEO datasets GSE36681 (https://www.ncbi.nlm.
nih.gov/gds/) is a public dataset containing 47 paired NSCLC tumors and a normal control group and we extracted the data concerning the expression of miR-338-3p between these two groups. transcription PCR (qRT-PCR) analyses were performed as previously described. 13 The primer sequences used for NRP1 mRNA detection were 5′-GAAAAATGCGAATGGCTGAT-3′ (forward) and 5′-AATGGCCCTGAAGACACAAC-3′ (reverse). The bulge-loop miRNA qRT-PCR primer sets (one RT primer and a pair of qPCR primers for each set) that were specific for miR-338-3p were designed and synthesized by RiboBio (RiboBio Co. Ltd, Guangzhou, Guangdong, China). The cycle threshold (Ct) values for NRP1 mRNA and miR-338-3p were equilibrated to those of ACTB (encoding beta-actin) mRNA and U6, respectively, which were used as internal controls. The △△Ct method was applied to calculate the relative expression levels of these mRNAs.
| Cell culture
| Western blotting analysis
Western blotting analysis was performed as previously described. 13 The antibodies used in the analysis were anti-NRP1 (A-12), anti- After 2 days, stable cells were selected with 400 μg/mL G418 (Amresco, Solon, OH).
| Cell proliferation analysis and drug treatment
The cell proliferation analysis and drug treatment were performed as previously described. 13 Briefly, according to the manufacturer's instructions, cell proliferation was examined using a Cell Counting Kit-8 (CCK-8 
| Wound healing, migration, and invasion assays
Cell motility was analyzed as previously described. 13 Briefly Transwell insert, and 800 μL of medium containing 10% FBS was placed into the lower chamber, followed by incubation at 37°C for 24 h. For the invasion assay, the inserts were coated with Matrigel matrix (BD Biosciences, Sparks, MD) diluted in serum-free medium and incubated at 37°C for 2 h. Finally, the cells were photographed and counted.
| Cell cycle analysis
According to the instructions of the Cell Cycle Analysis kit (Beyotime, improved the pharmacological properties, as described previously. 13 The tumor volume (V) was determined by measuring the tumour length (L) and width (W) using Vernier callipers and applying the formula
| Tumour metastasis model
In the experimental lung metastasis model, cells were resuspended in PBS (1 × 10 6 cells/100 μL PBS/mouse) before being injected into each mouse (BALB/c, 6 weeks old) via the tail vein on day 0. Eight weeks after tail vein injection, all mice were sacrificed, and the numbers of lung nodules were counted under a microscope after the appropriate tissues were stained with haematoxylin and eosin (H&E).
| Statistical analysis
Differences in NRP1 and miR-338-3p expression between NSCLC tissues (T) and adjacent noncancerous lung tissues (N) were analyzed using a paired t-test (two-tailed). The clinicopathological characteristics of the patients and the expression levels of mRNA and miRNA in the NSCLC samples were compared using nonparametric tests (the Mann-Whitney U test for comparisons between two groups, and the Kruskal-Wallis test for comparisons among three or more groups).
Two-way analysis of variance was used to determine the difference in cell growth between two groups. In all analyses, P < 0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using GraphPad Prism 5.02
(GraphPad, San Diego, CA) and SPSS 16.0 (IBM Corp., Armonk, NY) software.
3 | RESULTS
| NRP1 is upregulated in NSCLC tissues and cell lines
First, we found that NRP1 mRNA expression was significantly upregulated in lung carcinoma tissues relative to that in normal lung tissues in the public data deposited in the Oncomine database (http://www.oncomine.org, Figures 1A and 1B) . Furthermore, using data in the Gene GEPIA (http://gepia.cancer-pku.
cn/index.html) database, we found that high NRP1 expression in lung squamous cell carcinoma tissues was significantly associated with poor prognosis (P < 0.05, Figure 1C ). To further verify the prognostic role of NRP1 in NSCLC, Kaplan-Meier analyses and log-rank tests were performed. As shown in Figure 1D , high expression of NRP1 was significantly associated with poor survival in patients with NSCLC. Moreover, we detected NRP1 mRNA expression in 55-paired NSCLC tissues and adjacent noncancerous lung tissues. The results indicated that the NRP1 mRNA levels were significantly higher in NSCLC tissues than in adjacent noncancerous lung tissues (P < 0.05, Figure 1A and Supplemental Table S1 ). Next, we assessed the NRP1 mRNA and protein levels in three NSCLC cell lines and a bronchial epithelial cell line, BEAS-2B, using qRT-PCR and Western blotting ( Figure 1D ). The results showed that the NRP1 mRNA and protein levels were higher in the NSCLC cell lines than in the BEAS-2B cell line. Collectively, our data show that NRP1 is upregulated in NSCLC tissues and cell lines.
| The functional role of NRP1 in NSCLC cells
To elucidate the role of NRP1 in NSCLC, we first established A549
and H226 cell lines with stable knockdown of NRP1. The expression of NRP1 mRNA and protein was significantly reduced after the stable transfection of A549 and H226 cells with either of two NRP1
shRNAs (Figure 2A ). The CCK-8 assay showed that the growth of cells with stable knockdown of NRP1 was significantly inhibited compared with that of control cells at 24, 48, and 72 h ( Figure 2B ).
Next, we confirmed these findings via a clonogenic assay ( Figure 2C ). 
Moreover
| NRP1 promotes NSCLC metastasis in vivo
We next sought to clarify the mechanisms underlying NRP1-mediated tumor metastasis. NRP1-silenced and control A549 cells were injected into the tail vein of nude mice. As shown in Supplemental Figure S1 , mice injected with NRP1-silenced A549 cells developed fewer pulmonary metastatic nodules than those injected with the control cells. Figure 4D ) and Western blotting ( Figure 4E ). Collectively, our data show that NRP1 is a target of miR-338-3p in NSCLC cells.
| miR-338-3p targets NRP1 in NSCLC cells by binding to its 3′-UTR
| miR-338-3p expression is downregulated in NSCLC tissues and cell lines
Our previous study showed that miR-338-3p expression is lower in lung cancer tissues than in noncancerous tissues (Supplemental Figure S2A ). Considering that dysregulation of microRNAs is associated with multiple biological processes, we performed Gene
Ontology and pathway analyses and found that miR-338-3p was predicted to play a significant role in the pathogenesis of cancer (Supplemental Figure S2B) . To verify the miRNA array results, we examined the expression of miR-338-3p in 55-paired NSCLC tissues via qRT-PCR and found that its expression was significantly lower in tumor tissues than in paired noncancerous tissues ( Figure 4F and Supplemental Table S1 ). Furthermore, a public Gene Expression
Omnibus dataset (GSE36681) containing 47 NSCLC tissues and 47 normal lung tissues showed that miR-338-3p expression was downregulated in human NSCLC tissues ( Figure 4G ). We then examined miR-338-3p expression in three NSCLC cell lines and found that miR-338-3p levels were significantly lower in NSCLC cell lines than in BEAS-2B cells ( Figure 4H ).
| MiR-338-3p overexpression can inhibit NSCLC cell growth, cell cycle progression, and metastasis in vitro
To determine the function of miR-338-3p in NSCLC, we induced miR-338-3p overexpression using miR-338-3p mimics and then evaluated the effect of miR-338-3p on cell growth. CCK-8 assays
showed that NSCLC cells overexpressing miR-338-3p had significantly lower proliferation abilities than the control cells ( Figures 5A and 5B ). These results were confirmed using a clonogenic assay ( Figure 5C ), suggesting that miR-338-3p inhibits NSCLC cell proliferation.
To determine the mechanism by which miR-338-3p suppresses the proliferation of NSCLC cells, we examined the distribution of cell cycle phases using flow cytometry and found that a higher numbers of NSCLC cells overexpressing miR-338-3p than negative control cells were arrested in G0/G1 phase (P < 0.05, Figure 5D ). These results indicated that miR-338-3p inhibits cell proliferation in NSCLC cells via its effects on the cell cycle.
A wound-healing assay was performed to determine the role of miR-338-3p transfection in regulating the migration of A549 and H226 cells. As shown in Figure 5E , the migration rate of the cells transfected with the miR-338-3p mimics towards the wounded area was slower than that of the control cells. A Transwell assay using A549 and H226 cells further indicated that overexpression of miR-338-3p considerably suppressed the migration ability of A549
( Figure 5F ) and H226 cells ( Figure 5G ). Taken together, these observations suggest that miR-338-3p might function as a tumor suppressor in NSCLC.
A rescue experiment was performed to confirm that NRP1 is a functional target of miR-338-3p in A549 and H226 cells. First, cell lines stably overexpressing NRP1 were transfected with the miR-338-3p mimics or miR-NC. As shown in Supplemental Figure S3A 
| NRP1 and its associated pathways may be useful therapeutic targets
Recent evidence suggests that NRP1 affects tumor cell viability via the EGFR and ErbB2 signalling pathways in venous endothelial cells and multiple cancer cells. 7, 8 We thus hypothesized that NRP1 plays a role in the EGF signalling pathway and that knockdown of NRP1 expression might sensitize NSCLC cells to therapeutic agents. First, we assessed the levels of p-EGFR and its downstream signalling molecules. As shown in Figure 6A , the p-EGFR, p-FAK, and p-AKT levels were significantly lower in NRP1-silenced cells than in the control cells.
Correspondingly, the p-EGFR, p-FAK, and p-AKT levels were significantly higher in NRP1-overexpressing cells ( Figure 6C ). Furthermore, in the cell lines with stable NRP1 knockdown, the EGF-induced increase in p-EGFR expression was inhibited ( Figure 6B ). Moreover, our data showed that the p-EGFR, p-FAK, and p-AKT levels were significantly lower in the cell lines transfected with the miR-338-3p mimics than in the control cells ( Figure 6D ).
EGFR-TKI therapy significantly improves treatment outcomes of patients with lung cancers that harbour EGFR mutations; however, some patients with lung cancer with wild-type EGFR also benefit from EGFR-TKI therapy. 9,10 Therefore, we performed the following experiment: A549 and H226 cells (Mock), stable NRP1-silenced cells, and negative control cells (sh-NC) were treated with gefitinib or TAE226, an inhibitor of active FAK, which is characterized by phosphorylation at the Y397 residue. 26 Cell viability was assessed at 72 h after drug treatment. As shown in Supplemental Figure S4C and D, the viability of untreated A549 cells and sh-NC treated A549 cells decreased by 50% when exposed to gefitinib. Similar effects were observed when the cells were treated with TAE226 (P < 0.001, Figure 7D ). However, no significant changes were observed in control NSCLC cells exposed to either gefitinib or TAE226 (Supplemental Figure S4A and B). Our data seemed to indicate that NRP1 inhibition augments the effects of EGFR-TKIs.
| MiR-338-3p overexpression inhibits tumour growth in nude mice by targeting NRP1
MiR-338-3p is significantly downregulated in NSCLC; therefore, a miR-338-3p agomir was used for replacement therapy. As shown in ( Figures 7C and 7D ). These findings indicated that overexpression of miR-338-3p inhibits lung cancer cell growth in vivo through NRP1;
however, these findings need to be confirmed with a larger sample size.
| DISCUSSION
Although the survival rate for lung cancer has improved incrementally over the last several decades, the improvements in survival seen in other common malignancies have not been realized in lung cancer, which remains the leading cause of cancer mortality worldwide, including in China. 2 The current 5-year survival rate for lung cancer is a discouraging 15%. Therefore, understanding the molecular mechanisms of cancer development is important to develop effective therapies.
Recently, several studies have directly profiled miRNA expression in lung cancers, and unique groups of miRNAs that either characterize neoplastic tissues or identify patients with poor prognosis have been distinguished. [20] [21] [22] [23] [24] [25] Our previous study indicated that miR-338-3p
expression is significantly decreased in NSCLC, 25 consistent with the ) . B, The graph shows the tumor growth curves at the time of sacrifice with respect to the baseline measurements and after the administration of 2 nmol miR-338-3p agomir or NC agomir per mouse seven times every 4 days. C and D, qRT-PCR analysis of miR-338-3p levels and NRP1 mRNA expression in excised tumours transfected with the miR-338-3p agomir or the NC agomir; U6 and β-actin were used as the internal controls, respectively. E, A working model of the mechanistic interaction of miR-338-3p and NRP1 in controlling the EGFR signalling pathway: NRP1 targeted by miR-338-3p modulates EGFR signalling in NSCLC. *P < 0.05; **P < 0.01.
[Color figure can be viewed at wileyonlinelibrary.com] results of a study by Tan et al. 21 Previous research has suggested that miR-338-3p functions as a tumor suppressor and is downregulated in breast cancer, 27 nasopharyngeal carcinoma, 28 hepatocellular carcinoma, 29 gastric cancer, 30 and lung cancer. 31, 32 Recently, attention has focused on the expression of miR-338-3p and its target gene;
however, few studies have addressed the mechanism of action of miR-338-3p, especially its associated signalling transduction. 30 In the present study, we first confirmed the significantly decreased expression of miR-338-3p in NSCLC reportedly previously. At the cellular level, upregulation of miR-338-3p inhibited the proliferation, colony formation, invasion, and migration of NSCLC cells. Moreover, overexpressing miR-338-3p in NSCLC cells reduced tumorigenesis in vivo;
however, these results need to be confirmed in a larger sample in the future. Taken together, our results suggested a tumor suppressor role for miR-338-3p in NSCLC.
NRP1 is a transmembrane glycoprotein that acts as a co-receptor for numerous extracellular ligands, including class III/IV semaphorins, 33 certain isoforms of vascular endothelial growth factor (VEGF), 34 transforming growth factor beta (TGF-β), 35 and platelet-derived growth factor. 36 NRP1 is upregulated, and may be an independent predictor of cancer relapse and poor survival, in patients with NSCLC. 6 In addition, the synergistic effect of ErbB2 and NRP1 has been observed in venous endothelium. 7 Rizzolio et al demonstrated that NRP1-blocking antibodies and NRP1 silencing could counteract ligand-induced EGFR activation in cancer cells. 8 However, the above studies were unable to demonstrate whether transcriptional regulation events are involved in NRP1 inhibition and whether NRP1 inactivation enhances EGFR-TKI sensitivity. In the current study, using bioinformatic analysis and luciferase assays, we found that NRP1 is a target responses to latent and active TGF-β in breast cancer. 35 Therefore, whether NRP1 can affect TGF-β signalling in NSCLC requires further verification.
In summary, this study is the first to report that miR-338-3p expression is downregulated in NSCLC and is correlated with an increase in NRP1 expression. Furthermore, we found that miR-338-3p inhibits NRP1 expression by directly targeting the NRP1 3′-UTR, thereby repressing NSCLC cell proliferation and mobility.
Thus, our findings revealed the mechanistic interaction between miR-338-3p and NRP1 in NSCLC carcinogenesis. Importantly, our data seemed to indicate that miR-338-3p/NRP1 inhibition could augment the effects of EGFR-TKIs. Thus, miR-338-3p-mediated downregulation of NRP1 might lead to new therapeutic strategies for NSCLC ( Figure 7E ).
